Inequality of access to advanced therapies for patients with inflammatory arthritis: a postcode lottery?

OBJECTIVES: Advanced therapies (AT), including biologics, biosimilars and Janus kinase inhibitors, have dramatically improved the quality of life of patients with RA, PsA and axial spondyloarthritis (axSpA). Evidence-based criteria for prescribing these drugs in England and Wales is formulated by th...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaul, Arvind, Mistry, Jatin, Iagnocco, Annamaria, Baraliakos, Xenofon, Bosworth, Ailsa, McNicol, Iain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Concise Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634385/
https://www.ncbi.nlm.nih.gov/pubmed/34859176
http://dx.doi.org/10.1093/rap/rkab081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634385/
https://www.ncbi.nlm.nih.gov/pubmed/34859176
http://dx.doi.org/10.1093/rap/rkab081

Ejemplares similares